直接口服抗凝剂水平和血栓生成对术后出血的影响 [SONAR]:一个嵌套的病例对照研究
Joseph R Shaw1, Na Li2,3, Matthieu Grussé4
1Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Thrombosis and haemostasis
|January 21, 2025
概括
直接口服抗凝剂 (DOAC) 可以增加手术出血的风险. 即使低残留DOAC水平也会影响血栓生成,这是手术后出血的关键因素.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 手术性血液静止治疗方法
背景情况:
- 直接口服抗凝剂 (DOAC) 已被广泛使用,但它们对手术出血的影响尚未完全理解.
- 对影响手术血静的DOACs的特定度值仍然未知.
- 血栓生成试验 (TGA) 提供了一种评估凝血表型的方法.
研究的目的:
- 调查DOAC患者手术前TGA参数和术后出血之间的关联.
- 为了确定剩余的DOAC水平是否有助于这种关联.
- 探索TGA参数在DOAC相关出血中的调解作用.
主要方法:
- 一个嵌套的病例控制研究,使用PAUSE外科手术研究中的样本.
- 通过染色体抗Xa测定测量DOAC水平.
- 使用校准自动血栓学评估TGA参数.
- 统计分析包括一般化的线性混合模型和因果调解分析.
主要成果:
- 与对照组相比,在经历术后出血的患者 (病例) 中,残留DOAC水平显著更高.
- 所有TGA参数与剩余DOAC水平相关联.
- 增加TGA的延迟时间和峰值时间与更高的出血几率有关.
- 较高的峰值血栓和平均速度率指数与较低的出血几率有关.
- 因果调解分析证实,TGA参数调解了DOACs对出血的影响.
结论:
- 低残留DOAC水平可测量地影响了血栓生成.
- 改变的血栓生成参数是DOAC相关出血的一个重要因素.
- 这些发现突出了DOACs,凝血动态和手术出血风险之间的复杂相互作用.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
603
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
603
01:24Disorders of Hemostasis
693
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
693
01:20Extrinsic and Intrinsic Pathways of Hemostasis
5.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.1K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
01:16Clot Retraction and Fibrinolysis
3.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
464
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
464